Testing GBP-213 in adults with autosomal dominant polycystic kidney disease
Tests the drug GBP-213 in adults with autosomal dominant polycystic kidney disease.
Plain-language title generated from the registry record
Registry title: GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Early phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 with autosomal dominant polycystic kidney disease (ADPKD) that is getting worse quickly and kidney function that is moderately reduced but not very low.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- ADPKD diagnosed by a doctor that meets the criteria for rapidly progressive ADPKD. Kidney function (eGFR) must be between 30 and 100 mL/min/1.73m².
- Earlier treatment
- Cannot have used tolvaptan or a similar vasopressin V2 receptor antagonist, a somatostatin analog (such as lanreotide, pasireotide, octreotide), an mTOR inhibitor (such as everolimus, sirolimus), or any investigational drug within 30 days or 5 half-lives before dosing, whichever is longer.
Main reasons for not taking part
- Kidney cysts caused by another disease, such as autosomal recessive polycystic kidney disease or tuberous sclerosis complex
- Other serious or long-term liver or kidney diseases besides ADPKD, such as end-stage renal disease, hepatitis, cirrhosis, or kidney or liver cancer
- Use of the listed ADPKD-type drugs or any investigational drug within 30 days or 5 half-lives before dosing
- Heart attack, unstable angina, serious heart rhythm problem, class III or IV heart failure, or stroke within 6 months before dosing
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07891364, who can take part
Where in China
- Department of nephrology , Renji Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT07891364
- Record updated
- 23 October 2026
- Original description
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GBP-213 in patients with autosomal dominant polycystic kidney disease (ADPKD).Read full original descriptionShow less
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD).
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GBP-213 in patients with autosomal dominant polycystic kidney disease (ADPKD).
Inclusion: Age 18 to 65 years inclusive at the time of signing the ICF, regardless of sex; Clinically diagnosed with ADPKD; Meets criteria for rapidly progressive ADPKD; 100≥eGFR≥30mL/min/1.73m²; Understands the study procedures and voluntarily signs the written informed consent form.
Exclusion: Use of a vasopressin V2 receptor antagonist (e.g., tolvaptan), somatostatin analog (e.g., lanreotide, pasireotide, octreotide), mTOR inhibitor (e.g., everolimus, sirolimus), or any investigational drug within 30 days or 5 half-lives before dosing, whichever is longer; Any of the following cardiovascular or cerebrovascular events within 6 months before dosing: myocardial infarction, unstable angina, ventricular arrhythmia, New York Heart Association class III or IV heart failure, stroke, etc; Diagnosis of renal cystic disease due to other causes, such as autosomal recessive polycystic kidney disease, tuberous sclerosis complex, medullary cystic kidney disease, simple renal cysts, acquired cystic kidney disease, etc; Other severe or chronic hepatic or renal diseases in addition to ADPKD, such as glomerular or tubulointerstitial disease, end-stage renal disease, viral/alcoholic hepatitis, active autoimmune hepatitis, liver cancer, renal cancer, acute kidney injury, cirrhosis, etc.